Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer, Merck & Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their...
For women who aspire to healthcare's executive-level roles, advanced education and the willingness to take risks may not be enough. Surveys of corporate leadership and healthcare management point to a continued, though narrowing, disparity of women to men in leadership roles.
Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its global established pharmaceutical business.
The Institute of Medicine released four recommendations to address practices that often have left relevant medical research unpublished and useful data unattainable by independent researchers.
Baxter International is selling its vaccine business to Pfizer for $635 million as it prepares to split into two companies.
Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...
British drug maker AstraZeneca rejected Monday what its New York-based rival Pfizer called over the weekend its "final" takeover offer.
Pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer's sweetened takeover bid — worth $106 billion — just hours after it was levelled, describing it as inadequate.